Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Oculis Holding AGNASDAQ: OCS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of CHF 157.43K rose 28.0% year over year, ahead of the -7.4% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +20.4% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.0% holds above the trailing-twelve-month pace of -7.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 157.43K— QoQ
Last fiscal yearDec 2025
CHF 521.45K+28.4% YoY
LTMMar 2026
CHF 422.43K-7.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.0%——
1 year+28.4%——
3-year CAGR+20.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CHF · from the income statement

Latest · FY2025
521.45K CHF
Year-over-year change
+28.4%
4-year CAGR
+22.0%

Depreciation & Amortization vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.4% is the 5th highest of 6, against a peer median of +20.3%.
  • Depreciation & amortization amounts to 83.8% of revenue for OCS, versus a peer median of 20.5%.
OCS Competitors
Depreciation & Amortization for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HROWHarrow Health, Inc.LTM Mar 2026$19.5M USD+32.3%+88.3%7.3%
OCULOcular Therapeutix, Inc.LTM Mar 2026$4.63M USD+20.3%+27.0%8.9%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$2.45M USD+41.2%-1.9%32.1%
OCSOculis Holding AGLTM Mar 2026CHF 422.43K CHF-7.4%+20.4%83.8%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$119.64K USD+3.7%-17.0%35.9%
OKYOOKYO Pharma LimitedFY2025$2.56K USD-33.7%+3.2%—
Peer median (excluding OCS) —+20.3%+3.2%20.5%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.